Road To Biosimilar Interchangeability Could Be Through Market Experience

Demonstrating that a biosimilar is interchangeable with its reference product may be a subject for post-market studies rather than clinical trials, according to Kathleen Sanzo, partner at Morgan, Lewis and Bockius